Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

Haris Ali, Keri Maher, Ashwin Kishtagari, Sanjay R Mohan, Josef T. Prchal, Yi Chai, Christopher J. Walker, Trinayan Kashyap, Steve Kye, Srinivas K Tantravahi

Blood (2024) 144 (Supplement 1): 6676.

https://doi.org/10.1182/blood-2024-207778

Published: 2024

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Blood (2024) 144 (Supplement 1): 3179.

https://doi.org/10.1182/blood-2024-200999

Published: 2024

Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Blood (2024) 144 (Supplement 1): 658.

https://doi.org/10.1182/blood-2024-200925

Published: 2024

Journal Articles

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Blood (2024) 144 (Supplement 1): 655.

https://doi.org/10.1182/blood-2024-200312

Published: 2024

Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 479.

https://doi.org/10.1182/blood-2024-200717

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement

Taylor Kujawa, Charlotte B Wagner, Alexis Riddle, Jordan Robeson, Laura Bickel, Andrea Schindler, Srinivas K Tantravahi, Paul J. Shami

Blood (2024) 144 (Supplement 1): 5026.

https://doi.org/10.1182/blood-2024-198034

Published: 2024

Journal Articles

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Real-World Outcomes and Disparities in the Era of Novel Therapies, 2010-2021

Victoria A. Vardell, Srinivas K Tantravahi

Blood (2024) 144 (Supplement 1): 2334.

https://doi.org/10.1182/blood-2024-210983

Published: 2024

Journal Articles

Mixed Phenotype Acute Leukemias: Real-World Outcomes By Who Classifications 2010-2021

Victoria A. Vardell, Srinivas K Tantravahi

Blood (2024) 144 (Supplement 1): 2420.

https://doi.org/10.1182/blood-2024-211497

Published: 2024

Journal Articles

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Ehab L. Atallah, Michael S. Broder, Onyee Chan, Hannah Dalglish, Kathryn E. Flynn, Jeffrey Gilreath, Marisa Hine, Anthony M. Hunter, Michael J. Mauro, Javier Pinilla-Ibarz, Lindsay A.M. Rein, Neil P. Shah, Evan Stemper, Srinivas K Tantravahi, Jay Yang

Blood (2024) 144 (Supplement 1): 5052.

https://doi.org/10.1182/blood-2024-194617

Published: 2024

Journal Articles

Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors

Srinivas K. Tantravahi, Dominick Latremouille-Viau, Raj Desai, Soyon Lee, Jincy Paulose, Lincy Geevarghese, Annie Guérin, Shravanthi Seshasayee, Nadia Tabatabaeepour, Glorian P. Yen

Blood (2023) 142 (Supplement 1): 5119.

https://doi.org/10.1182/blood-2023-180759

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Exploratory Study on Impact of Comorbid Sleep Apnea Treatment in Patients with Polycythemia Vera and Essential Thrombocythemia

Krishna Sundar, Jihyun Song, Soo Jin Kim, Binal Shah, Kimberly Workman, Braxton Smith, Ellen Brooks, Gabrielle Matinkhah, Srinivas K. Tantravahi, Tsewang Tashi, Victor R. Gordeuk, Josef T. Prchal, Brynn Parsegov

Blood (2023) 142 (Supplement 1): 6414.

https://doi.org/10.1182/blood-2023-182884

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali

Blood (2023) 142 (Supplement 1): 622.

https://doi.org/10.1182/blood-2023-180844

Published: 2023

Journal Articles

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Justin M. Watts, Alessandro M. Vannucchi, Anthony M. Hunter, Brandon McMahon, Srinivas K. Tantravahi, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Emma Searle, Brandi N. Reeves, Prithviraj Bose, Rosa Ayala, Anna B. Halpern, Xuejun Chen, Lea M Burke, Feng Zhou, Fred Zheng, Pankit Vachhani

Blood (2023) 142 (Supplement 1): 750.

https://doi.org/10.1182/blood-2023-179428

Published: 2023

Journal Articles

Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A National Analysis of Overall Survival and Demographic Features

Victoria A. Vardell, Douglas J. Peters, Srinivas K. Tantravahi, Ami B. Patel

Blood (2022) 140 (Supplement 1): 1350–1352.

https://doi.org/10.1182/blood-2022-170734

Published: 2022

Journal Articles

Concerto (NCT04409639): A Phase 2 Trial of Cobimetinib in Newly Diagnosed and HMA-Treated CMML Patients with RAS Pathway Mutations

Ami B. Patel, Afaf Osman, Tony D. Pomicter, Srinivas K. Tantravahi, Michael W. Deininger

Blood (2022) 140 (Supplement 1): 4060–4061.

https://doi.org/10.1182/blood-2022-163570

Published: 2022

Journal Articles

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Connor Willis, David A. Sallman, Malinda Tan, Madeline Brendle, Vonetta L. Williams, Craig Comperatore, Trang Au, Srinivas K. Tantravahi, Najla Al Ali, Jeffrey A. Gilreath, Tibor Kovacsovics, Xiting Cao, Islam Sadek, Rami S. Komrokji, David Stenehjem

Blood (2022) 140 (Supplement 1): 5291–5292.

https://doi.org/10.1182/blood-2022-162622

Published: 2022

NARROW

Selinexor-Driven Regulation of Proinflammatory Cytokines May Lead to Stabilization of Hematologic Parameters and Bone Marrow Function in Patients with Myelofibrosis: Case Study from the Phase 1 Sentry Trial

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, Showed Durable Clinical Response and Sustained Hematological Improvement in Relapsed/Refractory Myelofibrosis Patients

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Evaluation of Pharmacist-Managed Thiopurine-Based Leukemia Maintenance Service Via a Collaborative Practice Agreement

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Real-World Outcomes and Disparities in the Era of Novel Therapies, 2010-2021

Mixed Phenotype Acute Leukemias: Real-World Outcomes By Who Classifications 2010-2021

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Incremental Burden Associated with Dose Escalation in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Complement Inhibitors

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Exploratory Study on Impact of Comorbid Sleep Apnea Treatment in Patients with Polycythemia Vera and Essential Thrombocythemia

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A National Analysis of Overall Survival and Demographic Features

Concerto (NCT04409639): A Phase 2 Trial of Cobimetinib in Newly Diagnosed and HMA-Treated CMML Patients with RAS Pathway Mutations

Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only